Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Praeruptorin A: Ferroptosis Workflow Guide
2026-08-13
Praeruptorin A connects DMT1-mediated iron overload with ferroptosis, offering a mechanism-led workflow for doxorubicin cardiomyopathy research. The same angular pyranocoumarin compound can be adapted to intestinal barrier, inflammation, and tumor-invasion assays when concentration, timing, and orthogonal readouts are carefully controlled.
-
RNF114, PARP1 Trapping, and BRCA Synthetic Lethality
2026-08-13
Li et al. identified RNF114 as a PARylation-dependent E3 ubiquitin ligase that regulates PARP1 removal from DNA lesions. Their work shows that nimbolide inhibits this pathway, intensifies PARP1 trapping, selectively kills BRCA-mutated cancer cells, and can overcome both intrinsic and acquired resistance to PARP inhibitors.
-
Rucaparib: From PARP Biology to Assay Design
2026-08-12
Rucaparib (AG-014699) is a powerful PARP1 research tool for connecting DNA repair, radiosensitization, and cancer-cell state. This guide translates spliceosome findings in hepatocellular carcinoma into biomarker-aware assay design without overstating clinical evidence.
-
Dabigatran etexilate: Direct Thrombin Assay Guide
2026-08-12
Build more reproducible thrombin, plasma-clotting, and platelet workflows with Dabigatran etexilate, while accounting for its prodrug chemistry and limited water solubility. This guide connects nanomolar potency data with practical stock preparation, assay selection, troubleshooting, and translational anticoagulant research.
-
Praeruptorin A Workflows for Inflammation Research
2026-08-11
Praeruptorin A is an angular pyranocoumarin compound suited to mechanism-led studies of ferroptosis, epithelial barrier injury, cardiomyopathy, and tumor invasion. This practical guide connects concentration selection, pathway readouts, dosing logistics, and troubleshooting to help researchers build reproducible preclinical workflows.
-
Single-Molecule Screening of Fast-Dissociating Antibodies
2026-08-11
Miyoshi and colleagues developed a semi-automated single-molecule TIRF microscopy assay that identifies specific antibodies with rapid dissociation directly from hybridoma cultures. The resulting Fab probes supported multiplexed super-resolution imaging and revealed rapid espin turnover within the dense, long-lived actin cores of inner-ear stereocilia.
-
Dacarbazine Workflows for Cancer Drug Response
2026-08-10
Build more informative Dacarbazine assays by separating growth inhibition from actual cell killing. This workflow combines DNA-damage profiling, endpoint-specific controls, and practical troubleshooting for malignant melanoma, Hodgkin lymphoma, and sarcoma models.
-
Streptavidin-FITC for LNP Trafficking
2026-08-09
A mechanistic and translational perspective on using Streptavidin-FITC to track biotinylated cargo, interpret LNP trafficking, and improve fluorescence-based assay strategy.
-
Gut Dysbiosis and Docetaxel Resistance in Prostate Cancer
2026-08-08
Zhong et al. connect antibiotic-associated gut dysbiosis with prostate cancer progression and reduced Docetaxel sensitivity through increased gut permeability, intratumoral lipopolysaccharide, and activation of the NF-κB–IL6–STAT3 axis. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient samples to identify Proteobacteria enrichment as a candidate marker of advanced disease.
-
Penicillin G Sodium: Applied Research Workflows
2026-08-07
Penicillin G Sodium is a natural penicillin antibiotic for controlled Gram-positive selection, infection-model benchmarking, and contamination management—not a universal cell-culture additive. This guide connects its bacterial cell wall mechanism with barrier-inflammation workflows while separating product-supported evidence from practical assay recommendations.
-
Cy5 TSA Fluorescence System Kit: Signal Amplification in IHC
2026-08-07
The Cy5 TSA Fluorescence System Kit delivers robust, HRP-catalyzed tyramide deposition for 100-fold signal amplification in immunohistochemistry and in situ hybridization. This kit enables sensitive detection of low-abundance targets and reduces reagent consumption, with fast, covalent Cy5 labeling for high-resolution imaging.
-
ST3GAL1-Mediated Sialylation Drives Fusobacterium Adhesion i
2026-08-06
This study identifies ST3GAL1-driven sialylation as a key mechanism enhancing the adhesion and colonization of Fusobacterium nucleatum in colorectal cancer cells. The findings deepen our understanding of host-microbe interactions in tumor microenvironments and highlight sialylated glycans as potential targets for investigating microbial persistence in cancer.
-
Solving Assay Challenges with EZ Cap™ Cy5 Firefly Luciferase
2026-08-06
Discover how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) addresses persistent laboratory challenges in mRNA delivery, cell viability, and bioluminescence assays. This scenario-driven guide offers validated, evidence-based insights for optimizing workflow sensitivity and reliability using APExBIO’s advanced dual-reporter mRNA.
-
Scenario-Driven Workflows with Bromodomain Inhibitor, (+)-JQ
2026-08-05
This article guides researchers through real laboratory challenges in apoptosis, viability, and inflammation assays, demonstrating how Bromodomain Inhibitor, (+)-JQ1 (SKU A1910) from APExBIO delivers data-backed, reproducible solutions. Each section addresses practical experimental bottlenecks, protocol optimization, and vendor reliability, offering scenario-based insights for biomedical scientists.
-
Fludarabine as a DNA Synthesis Inhibitor: Redefining Immuno-
2026-08-05
Explore how Fludarabine, a potent DNA synthesis inhibitor, uniquely enables advanced immuno-oncology research. This article delves into assay design, mechanistic synergy with T cell therapies, and practical guidance for optimizing experimental outcomes.